Viva In Vitro appoints Professor Ignacio Martín-Loeches to its Medical Advisory Board, strengthening its international clinical leadership in sepsis
Dr Ignacio Martín-Loeches joins Viva In Vitro Diagnostics as an advisor to its Medical Advisory Board, further strengthening a committee that already includes Dr Ricard Ferrer Roca (Vall d’Hebron University Hospital and leader of the SODIR research group).
Viva In Vitro Diagnostics, a Spanish biomedical company specialising in immunological medicine and the development of innovative solutions based on the NLRP3 inflammasome, has appointed Professor Ignacio Martín-Loeches as an external advisor to its Medical Advisory Board (MAB).
This appointment forms part of Viva In Vitro’s strategy to consolidate a Medical Advisory Board of excellence, composed of nationally and internationally recognised experts, with the aim of reinforcing the scientific and clinical rigour of its developments and accelerating the translation of biomedical research into real-world clinical practice.
Professor Ignacio Martín-Loeches brings an outstanding professional and academic career in the fields of intensive care medicine, severe infections and sepsis. He is Professor at Trinity College Dublin and Consultant in Intensive Care Medicine at St James’s Hospital, one of Europe’s leading university hospitals. His profile combines extensive clinical experience, academic leadership and a strong research background, positioning him as an international reference in sepsis and the management of critically ill patients.
Under this agreement, Professor Martín-Loeches will provide scientific, medical and technical advisory services to Viva In Vitro as a member of its Medical Advisory Board. His role will include supporting the evaluation of R&D projects, optimising the design and execution of clinical and preclinical studies, reviewing clinical protocols and procedures, contributing to training and scientific dissemination activities, and supporting the company’s international visibility and reputation within the medical and scientific community.
The appointment of Professor Martín-Loeches complements the previously announced collaboration with Dr Ricard Ferrer, Head of the Intensive Care Department at Vall d’Hebron University Hospital and one of the leading international authorities in sepsis, further consolidating a high-level Medical Advisory Board that reflects Viva In Vitro’s scientific ambition, clinical focus and international outlook.
“Having professionals such as Professor Ignacio Martín-Loeches and Dr Ricard Ferrer on our Medical Advisory Board clearly reflects the level of clinical excellence and rigour we apply to the development of our technology,” said Toni Vilaplana, Managing Director of Viva In Vitro. “Their expertise is essential to ensure that our diagnostic solutions address real clinical needs and to move forward with confidence in our clinical validation processes.”
This collaboration is closely aligned with the development of VIVA-ELISA®, a pioneering technology based on the functional activation of the NLRP3 inflammasome, designed to improve prognosis, immunological stratification and clinical decision-making in patients with sepsis. Viva In Vitro is one of the 40 companies selected by the EIC Transition programme (Horizon Europe), which has awarded the company €2.5 million in non-dilutive funding to advance this technology.
By strengthening its Medical Advisory Board, Viva In Vitro further consolidates its position as a reference biotech company in immunological medicine, with a clear commitment to clinical impact, scientific rigour and integration within leading hospital and research ecosystems across Europe.